4-Oxoretinol
Star0
Identification
- Generic Name
- 4-Oxoretinol
- DrugBank Accession Number
- DB02699
- Background
Not Available
- Type
- Small Molecule
- Groups
- Experimental
- Structure
- Weight
- Average: 300.4351
Monoisotopic: 300.20893014 - Chemical Formula
- C20H28O2
- Synonyms
- Not Available
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
- Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API
- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
- Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.
- Toxicity
Not Available
- Pathways
Pathway Category Retinol Metabolism Metabolic Vitamin A Deficiency Disease - Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareCyproterone acetate The therapeutic efficacy of Cyproterone acetate can be decreased when used in combination with 4-Oxoretinol. Demeclocycline The risk or severity of pseudotumor cerebri can be increased when 4-Oxoretinol is combined with Demeclocycline. Desogestrel The therapeutic efficacy of Desogestrel can be decreased when used in combination with 4-Oxoretinol. Dienogest The therapeutic efficacy of Dienogest can be decreased when used in combination with 4-Oxoretinol. Diethylstilbestrol The therapeutic efficacy of Diethylstilbestrol can be decreased when used in combination with 4-Oxoretinol. - Food Interactions
- Not Available
Categories
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as retinoids. These are oxygenated derivatives of 3,7-dimethyl-1-(2,6,6-trimethylcyclohex-1-enyl)nona-1,3,5,7-tetraene and derivatives thereof.
- Kingdom
- Organic compounds
- Super Class
- Lipids and lipid-like molecules
- Class
- Prenol lipids
- Sub Class
- Retinoids
- Direct Parent
- Retinoids
- Alternative Parents
- Diterpenoids / Fatty alcohols / Cyclohexenones / Primary alcohols / Organic oxides / Hydrocarbon derivatives
- Substituents
- Alcohol / Aliphatic homomonocyclic compound / Carbonyl group / Cyclic ketone / Cyclohexenone / Diterpenoid / Fatty acyl / Fatty alcohol / Hydrocarbon derivative / Ketone
- Molecular Framework
- Aliphatic homomonocyclic compounds
- External Descriptors
- retinoid (CHEBI:44597) / Retinoids (C16683)
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- 6FFM6M3NPT
- CAS number
- 62702-55-0
- InChI Key
- PLIUCYCUYQIBDZ-RMWYGNQTSA-N
- InChI
- InChI=1S/C20H28O2/c1-15(7-6-8-16(2)12-14-21)9-10-18-17(3)19(22)11-13-20(18,4)5/h6-10,12,21H,11,13-14H2,1-5H3/b8-6+,10-9+,15-7+,16-12+
- IUPAC Name
- 3-[(1E,3E,5E,7E)-9-hydroxy-3,7-dimethylnona-1,3,5,7-tetraen-1-yl]-2,4,4-trimethylcyclohex-2-en-1-one
- SMILES
- C\C(=C/CO)\C=C\C=C(/C)\C=C\C1=C(C)C(=O)CCC1(C)C
References
- General References
- Not Available
- External Links
- Human Metabolome Database
- HMDB0012329
- KEGG Compound
- C16683
- PubChem Compound
- 5289090
- PubChem Substance
- 46506951
- ChemSpider
- 4451124
- ChEBI
- 44597
- ZINC
- ZINC000012502479
- PDBe Ligand
- OXR
- PDB Entries
- 1x8l
Clinical Trials
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.0121 mg/mL ALOGPS logP 5.31 ALOGPS logP 4.03 Chemaxon logS -4.4 ALOGPS pKa (Strongest Acidic) 16.44 Chemaxon pKa (Strongest Basic) -2.2 Chemaxon Physiological Charge 0 Chemaxon Hydrogen Acceptor Count 2 Chemaxon Hydrogen Donor Count 1 Chemaxon Polar Surface Area 37.3 Å2 Chemaxon Rotatable Bond Count 5 Chemaxon Refractivity 98.62 m3·mol-1 Chemaxon Polarizability 36.68 Å3 Chemaxon Number of Rings 1 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter Yes Chemaxon Veber's Rule Yes Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
Property Value Probability Human Intestinal Absorption + 0.9975 Blood Brain Barrier + 0.8978 Caco-2 permeable + 0.8156 P-glycoprotein substrate Non-substrate 0.5424 P-glycoprotein inhibitor I Non-inhibitor 0.6712 P-glycoprotein inhibitor II Non-inhibitor 0.7751 Renal organic cation transporter Non-inhibitor 0.7733 CYP450 2C9 substrate Non-substrate 0.8048 CYP450 2D6 substrate Non-substrate 0.8559 CYP450 3A4 substrate Substrate 0.6797 CYP450 1A2 substrate Non-inhibitor 0.6685 CYP450 2C9 inhibitor Non-inhibitor 0.8946 CYP450 2D6 inhibitor Non-inhibitor 0.8688 CYP450 2C19 inhibitor Non-inhibitor 0.873 CYP450 3A4 inhibitor Non-inhibitor 0.7559 CYP450 inhibitory promiscuity Low CYP Inhibitory Promiscuity 0.8702 Ames test Non AMES toxic 0.6933 Carcinogenicity Non-carcinogens 0.8055 Biodegradation Ready biodegradable 0.7484 Rat acute toxicity 1.7980 LD50, mol/kg Not applicable hERG inhibition (predictor I) Weak inhibitor 0.8997 hERG inhibition (predictor II) Non-inhibitor 0.8974
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted GC-MS Spectrum - GC-MS Predicted GC-MS splash10-000i-1290000000-4649d7f3ab4f61c01faf Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS splash10-05ns-0890000000-e9b232f9185eb8fd595f Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS splash10-066r-0090000000-5f3288d6f55b38f48077 Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS splash10-067i-0190000000-52771a1dd74ee12792de Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS splash10-0gbj-1980000000-cf3db67523c69cb04b67 Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS splash10-0zfu-0390000000-4f577f46dd2c4453f50c Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS splash10-0i9c-2950000000-7044b059ab59f9ee5b9d Predicted 1H NMR Spectrum 1D NMR Not Applicable Predicted 13C NMR Spectrum 1D NMR Not Applicable - Chromatographic Properties
Collision Cross Sections (CCS)
Adduct CCS Value (Å2) Source type Source [M-H]- 194.5101981 predictedDarkChem Lite v0.1.0 [M-H]- 206.1174981 predictedDarkChem Lite v0.1.0 [M-H]- 186.19283 predictedDeepCCS 1.0 (2019) [M+H]+ 194.2759981 predictedDarkChem Lite v0.1.0 [M+H]+ 207.2951981 predictedDarkChem Lite v0.1.0 [M+H]+ 188.55084 predictedDeepCCS 1.0 (2019) [M+Na]+ 194.4268981 predictedDarkChem Lite v0.1.0 [M+Na]+ 205.9215981 predictedDarkChem Lite v0.1.0 [M+Na]+ 195.34741 predictedDeepCCS 1.0 (2019)
Drug created at June 13, 2005 13:24 / Updated at August 01, 2020 13:45